Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New CAR T-cell therapy eliminates MM and tumor propagating cells without fratricide in lab study

Publish date:: February 26, 2020

Key clinical point: CD229 CAR T cells are highly active in vitro and in vivo against MM plasma cells, memory B cells, and MM-propagating cells without fratricide.

Major finding: Using primary CD138+ tumor cells from three patients with plasma cell leukemia, a highly aggressive form of MM, which all showed high expression of CD229, the researchers found that CD229 CAR T cells exhibited high cytotoxic activity against these cells..

Study details: Study examined the effects of CD229 CAR T cells on MM-grafted cells in vivo in mice and in vitro in MM cell lines.

Disclosures: The study was funded by several nongovernmental organizations and the National Cancer Institute. Three of the authors are inventors on PCT application US2017/42840 “Antibodies and CAR T Cells for the Treatment of Multiple Myeloma” describing the therapeutic use of CD229 CAR T cells.

Citation:

Radhakrishnan SV et al. Nat Commun. 2020 Feb 7;11(1):798. doi: 10.1038/s41467-020-14619-z.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,